ClinicalTrialsFinder

Relapsed/Refractory Small Cell Lung Cancer Clinical Trials in Beijing, Beijing Municipality

1 recruitingBeijing, Beijing Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 1

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Relapsed/Refractory Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences55 enrolled2 locationsNCT07249879